Diseases of the Vitreo-Macular Interface - Hardcover

by Aniz Girach (Editor), Marc D. De Smet (Editor)

This clinically oriented book is the first to be devoted wholly to the diagnosis and treatment of vitreo-macular interface disease, characterized by a combination of vitreo-macular adhesion (VMA) and vitreo-macular traction (VMT) that is implicated in a variety of disorders. World-renowned experts in the field discuss epidemiologic, anatomic, and physiologic aspects, document the findings obtained with newer imaging techniques, such as spectral domain optical coherence tomography, describe the treatment options, and report on the results of preclinical and clinical trials, including some previously unpublished findings. This book will prove invaluable for ophthalmologists as we advance toward a future in which treatments of diseases such as age-related macular degeneration and diabetic retinopathy will likely require adjunctive therapy to tackle VMA/VMT concurrently.

Back Jacket

Disease of the vitreo-macular interface is characterized by vitreo-macular adhesion (VMA), which can lead to abnormal forces on the retina termed vitreo-macular traction (VMT). This combination of VMA and VMT can itself cause impairment of vision and is implicated in a variety of disorders, including wet age-related macular degeneration, diabetic retinopathy, macular edema, and macular hole. Vitreo-macular interface disease has recently begun to receive more attention owing in part to the advent of new imaging techniques that allow more accurate diagnosis and in part to advances in treatment.

This clinically oriented book is the first to be devoted wholly to the diagnosis and treatment of vitreo-macular interface disease. World-renowned experts in the field discuss epidemiologic, anatomic, and physiologic aspects, document the findings obtained with newer imaging techniques, such as spectral domain optical coherence tomography, describe the treatment options, and reporton the results of preclinical and clinical trials, including some previously unpublished findings. This book will prove invaluable for ophthalmologists as we advance toward a future in which treatments of diseases such as age-related macular degeneration and diabetic retinopathy will likely require adjunctive therapy to tackle VMA/VMT concurrently.

Author Biography

Aniz Girach, MB.ChB., MRCOphth., MRCGP, studied at Leeds University Medical School in the United Kingdom before specializing in ophthalmology. After working in the Department of Ophthalmology, Peterborough Hospitals Trust, Cambridgeshire, Dr. Girach became Ophthalmology Consultant (Europe) for the Grand Vision Group. He then joined Eli Lilly & Co. as Senior Global Ophthalmologist and was later promoted to Global Medical Director of the Global Ophthalmology Team. He subsequently performed a similar role for Merck & Co., before becoming Vice President of International Clinical Development for Alcon Inc. and Global Head of Ophthalmology at ThromboGenics NV, Belgium. Dr. Girach has served on various scientific advisory boards and is a reviewer for several leading journals, whilst maintaining his clinical practice part-time. He is the author of many journal articles, book chapters, and other publications on Retinal diseases and other diverse issues in ophthalmology.